Jonathan Glanzman, Allison Sacher, Thomas J. Fitzgerald, Alec Vaezi, Mark A. Rosen, Jeff M. Michalski, Michael V. Knopp, Kenneth Ulin, Paul Rava, David S Followill, Maryann Bishop-Jodoin, David J. Goff, and James M. Galvin
Quality assurance (QA) in complex head and neck cancer trials is essential. The need for QA is made more relevant with trials comprised of multiple end points, worldwide participation, and increasing use of adaptive strategies/advanced technology to validate/verify outcome analyses. Integration is necessary for tissue analysis, biomarker assessment, imaging, radiation therapy, chemotherapy, and/or targeted therapy for patients with new diagnosis, relapse, and second head and neck malignancies.